• LAST PRICE
    3.1700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.4400/ 3
  • Ask / Lots
    5.0700/ 1
  • Open / Previous Close
    0.0000 / 3.1700
  • Day Range
    ---
  • 52 Week Range
    Low 2.8054
    High 14.7800
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 3.21
TimeVolumeCADL
09:32 ET5023.26
09:36 ET9983.21
09:38 ET1003.3699
10:06 ET4003.45
10:14 ET41723.0715
10:15 ET5003.2574
10:19 ET13003.1
10:24 ET2003.07
11:18 ET2502.8054
11:29 ET1702.9878
11:49 ET2003.075
12:20 ET1003.25
01:08 ET1003.25
02:00 ET3253.159
03:52 ET1003.175
03:56 ET1003.17
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCADL
Candel Therapeutics Inc
91.0M
-2.5x
---
United StatesCAPR
Capricor Therapeutics Inc
90.7M
-3.9x
---
United StatesXLO
Xilio Therapeutics Inc
91.2M
-1.1x
---
United StatesELYM
Eliem Therapeutics Inc
91.9M
-1.8x
---
United StatesANIX
Anixa Biosciences Inc
91.4M
-5.8x
---
United StatesGALT
Galectin Therapeutics Inc
87.9M
-2.6x
---
As of 2022-07-06

Company Information

Candel Therapeutics, Inc is a clinical stage biopharmaceutical company. The Company is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Its approach combines a knowledge of viral immunotherapy with clinical experience across a range of indications. Its product candidate, CAN-2409 program, is in Phase III clinical trial. Its lead HSV product candidate, CAN-3110, is in Phase I clinical trial. The Company also designs candidates based on its HSV platform for the treatment of solid tumors. The Company’s oncolytic viral immunotherapy platforms is based on genetically modified adenovirus and herpes simplex virus (HSV) constructs.

Contact Information

Headquarters
117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
Phone
617-916-5445
Fax
302-655-5049

Executives

Independent Chairman Of the Board
Carrie Cox
President, Chief Executive Officer, Director
Paul Tak
Founder, Chief Scientific Officer, Director
Estuardo Aguilar-cordova
Chief Financial Officer
John Canepa
Vice President - Head of Research
Francesca Barone

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$91.0M
Revenue (TTM)
$124.0K
Shares Outstanding
28.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.26
Book Value
$2.24
P/E Ratio
-2.5x
Price/Sales (TTM)
733.5
Price/Cash Flow (TTM)
---
Operating Margin
-24,238.71%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.